{"id":"W3194210289","doi":"10.1136/jitc-2021-003188","title":"Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EUSA Pharma; Ipsen; Pharmacyclics; Eisai; Incyte; Genentech; Les Laboratories Pierre Fabre; AstraZeneca; Pfizer; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Adjuvant; Ipilimumab; Adverse effect; Oncology; Internal medicine; Proportional hazards model; Melanoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002968871,0.000225521,0.0005270495,0.0002770509,0.0001031519,0.0004030804,0.0002023194,0.0002140542,0.0006202547],"category_scores_gemma":[0.002298673,0.00007283669,0.0006727926,0.0002870054,0.0001695675,0.0002314515,0.0001854946,0.0004277717,0.0000878943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003817949,"about_ca_system_score_gemma":0.0003993579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002989769,"about_ca_topic_score_gemma":0.0006146052,"domain_scores_codex":[0.9994251,0.0002385051,0.00006264137,0.00008563204,0.0001345072,0.00005366633],"domain_scores_gemma":[0.9974641,0.0007758421,0.001181403,0.0001276524,0.0002258757,0.0002250801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07165655,0.001232476,0.8389315,0.0004874479,0.001441377,0.0001019753,0.00008401435,0.002799628,0.007314311,0.00007913717,0.0004600059,0.07541159],"study_design_scores_gemma":[0.002583117,0.03514453,0.947517,0.00006637913,0.001386309,0.0004904066,0.00005863448,0.006967445,0.004325958,0.0002151824,0.001221311,0.00002362707],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983637,0.0009602459,0.0001989262,0.00002875939,0.000004301677,0.00004234426,0.0001614851,0.000005186932,0.0002351935],"genre_scores_gemma":[0.9992288,0.0001923477,0.0001652185,0.00002180295,0.00001129825,0.00003293105,0.0002478396,0.000001940544,0.00009773482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002968871,"threshold_uncertainty_score":0.01570112,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03369585980913195,"score_gpt":0.3512298565537758,"score_spread":0.3175339967446438,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}